Patricia Cost

Component Costs of CAR-T Therapy in Addition to Treatment Acquisition Costs in Patients with Multiple Myeloma

Sundar Jagannath, N.R. Joseph, Concetta Crivera et al. · Oncology and Therapy · 2023 · 31 citations · Full text

Life Sciences, Immunology, Pharmacoeconomics +17

Real-world treatment patterns and outcomes in relapsed/refractory multiple myeloma (1-3 prior lines): Flatiron database

Binod Dhakal, Hermann Einsele, Jordan M. Schecter et al. · Blood Advances · 2024 · 15 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting

Winfried Alsdorf, Joris Diels, Francesca Ghilotti et al. · Journal of Comparative Effectiveness Research · 2024 · 12 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2–4 prior lines of therapy: a matching-adjusted indirect comparison

Noffar Bar, Joris Diels, Suzy Van Sanden et al. · Current Medical Research and Opinion · 2024 · 11 citations

Medicine, Internal Medicine, Oncology +16

Comparative Efficacy of Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 2-4 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison

Noffar Bar, Joris Diels, Suzy Van Sanden et al. · Blood · 2023 · 10 citations

Medicine, Hematology, Pharmacology +17